Bob Zhang is the founder of Epigenic Therapeutics. Epigenic Therapeutics has raised $92M in total funding. Latest round: Series B.
Bob Zhang is the Co-founder & CEO of Epigenic Therapeutics, a clinical-stage biotechnology company developing next-generation gene modulation therapy using epigenome regulation to treat prevalent diseases. The company completed a $60 million Series B financing in September 2025 and a $32 million Series A round in August 2023. Epigenic Therapeutics focuses on advancing epigenetic modulation technologies, with a proprietary EPIREG™ technology platform that enables efficient, durable, and specific silencing of target genes through precise DNA methylation and histone modification.
Full founder directory · Investor directory · Company funding database · Fundraising library